A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.


Updates from The Motley Fool

Latest updates on Halozyme Therapeutics from Fool.com.  The Fool has written over 100 articles on Halozyme Therapeutics.


Stock Performance

View Interactive HALO Charts
Sponsored by

Key Data Points

Primary metrics and data points about Halozyme Therapeutics.
Current Price: $12.79
Prev Close: $12.75
Open: $12.78
Bid: $12.78
Ask: $12.79
Day's Range: $12.47 - $12.86
52wk Range: $7.70 - $15.20
Volume: 293,209
Avg Vol 1,072,069
Market Cap: $2B
P/E (ttm): -14.01
EPS (ttm): ($0.91)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Halozyme Therapeutics.
CAPS Rating 3 out of 5
 
300 Outperform
43 Underperform
CAPS All Stars
 
49 Outperform
10 Underperform

How do you think Halozyme Therapeutics will perform against the market?



You pick for Halozyme Therapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Gregory I. Frost, CEO

78% Approve

Based on 6 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Halozyme Therapeutics.

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers